TY  - JOUR
AU  - Ungvári, Zoltán István
AU  - Fekete, Mónika
AU  - Varga, Péter
AU  - Lehoczki, Andrea Marianna
AU  - Fekete, János Tibor
AU  - Ungvári, Anna Sára
AU  - Győrffy, Balázs
TI  - Overweight and obesity significantly increase colorectal cancer risk: a meta-analysis of 66 studies revealing a 25–57% elevation in risk
JF  - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)
J2  - GEROSCIENCE
VL  - In press
PY  - 2024
SP  - In press
SN  - 2509-2715
DO  - 10.1007/s11357-024-01375-x
UR  - https://m2.mtmt.hu/api/publication/35447386
ID  - 35447386
AB  - The incidence of colorectal cancer (CRC) has been steadily rising, and obesity has been identified as a significant risk factor. Numerous studies suggest a strong correlation between excess body weight and increased risk of CRC, but comprehensive quantification through pooled analysis remains limited. This study aims to systematically review and meta-analyze the existing literature to evaluate the association between obesity and CRC risk, considering variations across sex and study designs. A systematic literature search was conducted in PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify randomized controlled trials and human clinical trials from 1992 to 2024. Statistical analysis was performed using the https://metaanalysisonline.com web application using a random effects model to estimate the pooled hazard rates (HR). Forest plots, funnel plots, and Z-score plots were utilized to visualize results. We identified 52 clinical trials and 14 case–control studies, encompassing a total of 83,251,050 and 236,877 subjects, respectively. The pooled analysis indicated that obesity significantly increased the prevalence of CRC (HR = 1.36, 95% CI = 1.24–1.48, p  < 0.01). This effect was consistent across sexes, with HRs of 1.57 (95% CI = 1.38–1.78, p  = 0.01) for males and 1.25 (95% CI = 1.14–1.38, p  < 0.01) for females. Case–control studies specifically showed an effect, but with marginal significance only (HR = 1.27, 95% CI = 0.98–1.65, p  = 0.07). The Z-score plot indicated the need for additional analysis in the case–control group. A significant heterogeneity was observed across studies in all four settings. This meta-analysis provides robust evidence that obesity is a significant risk factor for colorectal cancer, with an overall hazard rate indicating a 36% increased risk. The effect is pronounced across both sexes, with males showing a slightly higher risk compared to females. Although case–control studies showed a weaker association, the overall trend supports the link between obesity and CRC. These results underscore the importance of public health interventions aimed at reducing obesity to potentially lower the risk of colorectal cancer.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Dugo, Matteo
AU  - Huang, Chiun-Sheng
AU  - Egle, Daniel
AU  - Bermejo, Begoña
AU  - Zamagni, Claudio
AU  - Seitz, Robert S
AU  - Nielsen, Tyler J
AU  - Thill, Marc
AU  - Antón-Torres, Antonio
AU  - Russo, Stefania
AU  - Ciruelos, Eva Maria
AU  - Schweitzer, Brock L
AU  - Ross, Douglas T
AU  - Galbardi, Barbara
AU  - Greil, Richard
AU  - Semiglazov, Vladimir
AU  - Győrffy, Balázs
AU  - Colleoni, Marco
AU  - Kelly, Catherine M
AU  - Mariani, Gabriella
AU  - Del Mastro, Lucia
AU  - Blasi, Olivia
AU  - Callari, Maurizio
AU  - Pusztai, Lajos
AU  - Valagussa, Pinuccia
AU  - Viale, Giuseppe
AU  - Gianni, Luca
AU  - Bianchini, Giampaolo
TI  - The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
JF  - CLINICAL CANCER RESEARCH
J2  - CLIN CANCER RES
PY  - 2024
SN  - 1078-0432
DO  - 10.1158/1078-0432.CCR-24-0149
UR  - https://m2.mtmt.hu/api/publication/35427260
ID  - 35427260
AB  - We assessed the 27-gene RT-qPCR-based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neoadjuvant carboplatin/nab-paclitaxel chemotherapy (CT) plus atezolizumab with CT alone in stage II/III triple-negative breast cancer. We also assessed the predictive function of the immuno-oncology (IO) score in expression data of patients treated with pembrolizumab plus paclitaxel (N = 29) or CT alone (N = 56) in the I-SPY2 trial.RNA-seq data were obtained from pretreatment core biopsies from 242 (93.8%) of the 258 patients in the per-protocol-population. The DetermaIO RT-qPCR test, performed in the CAP/CLIA-accredited laboratory of Oncocyte Corp., was available for 220 patients (85.3%). A previously established threshold was used to assign DetermaIO-positive versus DetermaIO-negative status. Publicly available microarray data were used from I-SPY2.IO scores calculated from RNA-seq and RT-qPCR data were highly concordant. In neoTRIPaPDL1, DetermaIO-positive cancers (N = 92, 41.8%) had pathologic complete response (pCR) rates of 69.8% and 46.9% in the CT + atezolizumab and CT arms, respectively. In DetermaIO-negative cases, pCR rates were similar in both arms (44.6% vs. 49.2%; interaction test P = 0.04). PDL1 protein expression and stromal tumor-infiltrating lymphocyte count were not predictive of differential benefit from atezolizumab. In I-SPY2, IO-positive cancers (45.9%) had pCR rates of 85.7% and 16%, with and without immunotherapy, respectively. In IO-negative cancers, pCR rates were 46.7% versus 16.1%.DetermaIO identified patients who benefited from neoadjuvant immunotherapy resulting in improved pCR rate, independently of PDL1.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Barozzi, I.
AU  - Slaven, N.
AU  - Canale, E.
AU  - Lopes, R.
AU  - Amorim, Monteiro Barbosa I.
AU  - Bleu, M.
AU  - Ivanoiu, D.
AU  - Pacini, C.
AU  - Mensa', E.
AU  - Chambers, A.
AU  - Bravaccini, S.
AU  - Ravaioli, S.
AU  - Győrffy, Balázs
AU  - Dieci, M.V.
AU  - Pruneri, G.
AU  - Galli, G.G.
AU  - Magnani, L.
TI  - A Functional Survey of the Regulatory Landscape of Estrogen Receptor-Positive Breast Cancer Evolution
JF  - CANCER DISCOVERY
J2  - CANCER DISCOV
VL  - 14
PY  - 2024
IS  - 9
SP  - 1612
EP  - 1630
PG  - 19
SN  - 2159-8274
DO  - 10.1158/2159-8290.CD-23-1157
UR  - https://m2.mtmt.hu/api/publication/35309371
ID  - 35309371
N1  - Center for Cancer Research, Medical University of ViennaVienna, Austria            
            Department of Surgery and Cancer, Imperial College London, London, United Kingdom            
            Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States            
            Disease area Oncology, Novartis Biomedical Research, Basel, Switzerland            
            IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy            
            Faculty of Medicine and Surgery, "Kore" University of Enna, Enna, Italy            
            Department of Bioinformatics, Semmelweis UniversityBudapest, Hungary            
            Department of Biophysics, Medical School, University of Pecs, Pecs, Hungary            
            Cancer Biomarker Research Group, Institute of Molecular Life Sciences, Research Centre for Natural SciencesBudapest, Hungary            
            Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy            
            Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy            
            Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy            
            Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy            
            Breast Cancer Now Toby Robins Research Centre, Institute of Cancer, Research, London, United Kingdom            
            Export Date: 24 September 2024
LA  - English
DB  - MTMT
ER  - 

TY  - GEN
AU  - Szadai, Leticia
AU  - Bartha, Áron
AU  - Pla, Parada Indira
AU  - Lakatos, Alexandra
AU  - Pál, Dorottya
AU  - Lengyel, Anna Sára
AU  - Pinto, de Almeida Natália
AU  - Jánosi, Ágnes Judit
AU  - Nogueira, Fábio
AU  - Szeitz, Beáta
AU  - Doma, Viktória
AU  - Woldmar, Nicole
AU  - Guedes, Jéssica
AU  - Újfaludi, Zsuzsanna
AU  - Páhi, Zoltán Gábor
AU  - Pankotai, Tibor
AU  - Kim, Yonghyo
AU  - Győrffy, Balázs
AU  - Baldetorp, Bo
AU  - Welinder, Charlotte
AU  - Szász, Attila Marcell
AU  - Betancourt, Lazaro
AU  - Gil, Jeovanis
AU  - Appelqvist, Roger
AU  - Kwon, Ho-Jeong
AU  - Kárpáti, Sarolta
AU  - Kuras, Magdalena
AU  - Rodriguez, Murillo Jimmy
AU  - Németh, István Balázs
AU  - Malm, Johan
AU  - Fenyö, David
AU  - Pawłowski, Krzysztof
AU  - Horvatovich, Peter
AU  - Wieslander, Elisabet
AU  - Kemény, Lajos Vince
AU  - Domont, Gilberto
AU  - Marko-Varga, György
AU  - Sanchez, Aniel
TI  - Predicting immune checkpoint therapy response in three independent metastatic melanoma cohorts
PY  - 2024
DO  - 10.1101/2024.05.01.592032
UR  - https://m2.mtmt.hu/api/publication/35262423
ID  - 35262423
LA  - English
DB  - MTMT
ER  - 

TY  - CONF
AU  - Dobolyiné Renner, Éva
AU  - Dóra, Fanni
AU  - Munkácsy, Gyöngyi
AU  - Dóczi, Tamás Péter
AU  - Győrffy, Balázs
AU  - Dobolyi, Árpád
AU  - Palkovits, Miklós
TI  - RNA degradation in human brain tissue samples depends on multiple factors
T2  - International Neuroscience Conference, Pécs 2024
PY  - 2024
SP  - 285
EP  - 285
PG  - 1
UR  - https://m2.mtmt.hu/api/publication/35208573
ID  - 35208573
AB  - Recent developments in RNA sequencing increased the use of human brain tissue samples in understanding transcriptional alterations in neurological and psychiatric diseases. The human brain tissue samples typically cannot be processed immediately for RNA isolation. Rather, the dissection of the brain is usually carried out hours after the death is confirmed. Subsequently, the brains are stored frozen or in fixative before dissection of RNA. Even the rare surgical samples cannot be processed on the site and need to be transported to a laboratory for RNA isolation. RNA is not stable as it can be degraded by RNases as well as its chemical decomposition can happen. These processes depend on the microenvironment around the RNA, which may not be the same for the different samples. Therefore, in the present study, we aimed to examine RNA quality in different human brain samples stored in the Human Brain Tissue Bank of the Semmelweis University. RNA quality was assessed by measuring the RNA integrity number (RIN) following an RNA purification protocol combining the Trizol method and the columnar purification steps. RNA quality varied depending on the brain, which the samples were dissected from. The position of the brain tissue sample within the brain had less effect on the RNA quality. Interestingly, once the RNA quality was good in a particular brain, it remained stable for several hours and showed only limited degradation with postmortem time (2 to 10 hours at room temperature). In contrast, neurosurgical samples (brain tissue removed from the brain during neurosurgery), which have a small size, showed fast degradation if stored at room temperature for 1 min to 3 hours. In addition to these factors, the RNA quality also showed some dependency on the types of disease the patient suffered from. In contrast, sex and age dependence was not found. These data suggest that the brains have to be tested for RNA quality and dissections for transcriptomics have to be performed only from selected brains with high RIN numbers. In turn, a good quality RNA (better than RIN number 7) can be obtained from many brains stored at -80 °C if properly processed.

Grant support was provided by HAS NAP2022-I-3/2022 and NAP2022-I-4/2022 NAP3 of the Hungarian Academy of Sciences, EFOP-3.6.3-VEKOP-16-2017-00009 and Thematic Excellence Program of the Semmelweis University.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Major, Enikő
AU  - Lin, Kuan-Hung
AU  - Lee, Sue Chin
AU  - Káldi, Krisztina
AU  - Győrffy, Balázs
AU  - Tigyi, Gabor
AU  - Benyó, Zoltán
TI  - LPA suppresses HLA-DR expression in human melanoma cells: a potential immune escape mechanism involving LPAR1 and DR6-mediated release of IL-10
JF  - ACTA PHARMACOLOGICA SINICA
J2  - ACTA PHARMACOL SIN
VL  - 2024
PY  - 2024
PG  - 9
SN  - 1671-4083
DO  - 10.1038/s41401-024-01373-x
UR  - https://m2.mtmt.hu/api/publication/35195205
ID  - 35195205
N1  - Funding Agency and Grant Number: Semmelweis University
            Funding text: Open access funding provided by Semmelweis University.
AB  - While immune checkpoint inhibitors (ICIs) are promising in the treatment of metastatic melanoma, about half of patients do not respond well to them. Low levels of human leukocyte antigen-DR (HLA-DR) in tumors have been shown to negatively influence prognosis and response to ICIs. Lysophosphatidic acid (LPA) is produced in large amounts by melanoma and is abundantly present in the tumor microenvironment. LPA induces the release of various cytokines and chemokines from tumor cells, which affect cancer development, metastasis, and tumor immunity. In the present study, we investigated the role of LPA-induced IL-10 release in regulating HLA-DR expression and the underlying mechanisms in human melanoma cells. We showed that LPA (0.001–10 μM) dose-dependently increased DR6 transcript levels through activating LPAR1 in HEK293T cells. Knockdown of NF-κB1 abrogated the LPA-increased DR6 expression without affecting basal DR6 expression in both A2058 and A375 melanoma cell lines. LPA (10 µM) significantly increased IL-10 transcripts in A2058 and A375 melanoma cells, the effect was abolished by pharmacological inhibition of LPAR1 or knockdown of DR6. We found a statistically significant correlation between the expression of LPAR1, DR6 and IL-10 in human melanoma tissue and an association between increased expression of LPAR1 and reduced effectiveness of ICI therapy. We demonstrated that LPA (10 µM) markedly suppressed HLA-DR expression in both A375 and A2058 melanoma cells via activating the LPAR1-DR6-IL-10 pathway. These data suggest that the LPAR1-DR6-IL-10 autocrine loop could constitute a novel mechanism used by tumor cells to evade immunosurveillance by decreasing HLA-DR expression.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Murmu, Ankita
AU  - Győrffy, Balázs
TI  - Artificial intelligence methods available for cancer research
JF  - FRONTIERS OF MEDICINE
J2  - FRONT MEDIC
VL  - In press
PY  - 2024
PG  - 20
SN  - 2095-0217
DO  - 10.1007/s11684-024-1085-3
UR  - https://m2.mtmt.hu/api/publication/35172465
ID  - 35172465
AB  - Cancer is a heterogeneous and multifaceted disease with a significant global footprint. Despite substantial technological advancements for battling cancer, early diagnosis and selection of effective treatment remains a challenge. With the convenience of large-scale datasets including multiple levels of data, new bioinformatic tools are needed to transform this wealth of information into clinically useful decision-support tools. In this field, artificial intelligence (AI) technologies with their highly diverse applications are rapidly gaining ground. Machine learning methods, such as Bayesian networks, support vector machines, decision trees, random forests, gradient boosting, and K-nearest neighbors, including neural network models like deep learning, have proven valuable in predictive, prognostic, and diagnostic studies. Researchers have recently employed large language models to tackle new dimensions of problems. However, leveraging the opportunity to utilize AI in clinical settings will require surpassing significant obstacles-a major issue is the lack of use of the available reporting guidelines obstructing the reproducibility of published studies. In this review, we discuss the applications of AI methods and explore their benefits and limitations. We summarize the available guidelines for AI in healthcare and highlight the potential role and impact of AI models on future directions in cancer research.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Menyhart, Otilia
AU  - Fekete, János Tibor
AU  - Győrffy, Balázs
TI  - Inflammation and Colorectal Cancer: A Meta-Analysis of the Prognostic Significance of the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI)
JF  - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
J2  - INT J MOL SCI
VL  - 25
PY  - 2024
IS  - 15
PG  - 18
SN  - 1661-6596
DO  - 10.3390/ijms25158441
UR  - https://m2.mtmt.hu/api/publication/35172447
ID  - 35172447
AB  - The overall prognosis for colorectal cancer (CRC) remains challenging as the survival time varies widely, even in patients with the same stage of disease. Recent studies suggest prognostic relevance of the novel markers of systemic inflammation, the systemic immune-inflammation index (SII), and the systemic inflammation response index (SIRI). We conducted a comprehensive meta-analysis to assess the prognostic significance of the SII and the SIRI in CRC. We searched the relevant literature for observational studies, and random effects models were employed to conduct a statistical analysis using the metaanalysisonline.com platform. Pooled effect sizes were reported with hazard ratios (HRs) and corresponding 95% confidence intervals (CI). Data from 29 studies published between 2016 and 2024, comprising 10,091 participants, were included in our meta-analysis on SII. CRC patients with high SII levels had worse disease outcomes, which were associated with poor OS (HR: 1.75; 95% CI: 1.4-2.19) and poor PFS/DFS/RFS (HR: 1.25; 95% CI: 1.18-1.33). This increased risk of worse OS was present irrespective of the treatment strategy, sample size (<220 and >= 220), and cutoff used to define high and low SII (<550 and >= 550) groups. Based on data from five studies comprising 2362 participants, we found a strong association between the high SIRI and worse OS (HR: 2.65; 95% CI: 1.6-4.38) and DFS/RFS (HR: 2.04; 95% CI: 1.42-2.93). According to our results, both the SII and SIRI hold great promise as prognostic markers in CRC. Further validations are needed for their age- and stage-specific utility in the clinical routine.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ungvári, Zoltán István
AU  - Fekete, Mónika
AU  - Fekete, János Tibor
AU  - Grosso, Giuseppe
AU  - Ungvári, Anna Sára
AU  - Győrffy, Balázs
TI  - Adherence to the Mediterranean diet and its protective effects against colorectal cancer: a meta-analysis of 26 studies with 2,217,404 participants
JF  - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)
J2  - GEROSCIENCE
VL  - In press
PY  - 2024
PG  - 17
SN  - 2509-2715
DO  - 10.1007/s11357-024-01296-9
UR  - https://m2.mtmt.hu/api/publication/35162223
ID  - 35162223
N1  - Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States            
            Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, United States            
            Oklahoma Center for Geroscience and Healthy Brain Aging, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States            
            Department of Health Promotion Sciences, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States            
            International Training Program in Geroscience, Doctoral College/Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary            
            Institute of Preventive Medicine and Public Health, Semmelweis University, Semmelweis University, Budapest, Hungary            
            Department of Bioinformatics, Semmelweis University, Budapest, 1094, Hungary            
            Cancer Biomarker Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, H-1117, Hungary            
            Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy            
            Center for Human Nutrition and Mediterranean Foods (NUTREA), University of Catania, Catania, Italy            
            Department of Biophysics, Medical School, University of Pecs, Pecs, H-7624, Hungary            
            Cited By :1            
            Export Date: 23 September 2024            
            Correspondence Address: Ungvari, A.; Institute of Preventive Medicine and Public Health, Hungary; email: Ungann2004@gmail.com            
            Funding details: Ministry of Innovation, Science and Technology, MOST            
            Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA            
            Funding details: RRF-2.3.1–21-2022–00015, 135784            
            Funding details: 101004093/ EUniWell/EAC-A02-2019 / EAC-A02-2019–1            
            Funding details: National Cancer Institute, NCI, R01CA255840, TKP2021-NKTA-47            
            Funding details: National Cancer Institute, NCI            
            Funding details: National Institute on Aging, NIA, R01AG068295, R01AG070915, RF1AG072295, R01AG055395            
            Funding details: National Institute on Aging, NIA            
            Funding details: National Institute of Neurological Disorders and Stroke, NINDS, R01NS100782            
            Funding details: National Institute of Neurological Disorders and Stroke, NINDS            
            Funding details: RRF-2.3.1–21-2022–00003            
            Funding text 1: Open access funding provided by Semmelweis University. This work was supported by grants from the National Institute on Aging (RF1AG072295, R01AG055395, R01AG068295; R01AG070915), the National Institute of Neurological Disorders and Stroke (R01NS100782), the National Cancer Institute (R01CA255840). AU was supported by TKP2021-NKTA-47, implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-NKTA funding scheme, by funding through the National Cardiovascular Laboratory Program (RRF-2.3.1\\u201321-2022\\u201300003) and by the National Laboratory for Drug Research and Development (PharmaLab, RRF-2.3.1\\u201321-2022\\u201300015) provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, Project no. 135784 implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the K20 funding scheme and the European University for Well-Being (EUniWell) program (grant agreement number: 101004093/ EUniWell/EAC-A02-2019 / EAC-A02-2019\\u20131). The 4.0 version of ChatGPT, developed by OpenAI, was used as a language tool to refine our writing, enhancing the clarity of our work.
AB  - Colorectal cancer (CRC) is a major global health concern and represents a significant public health challenge in Hungary, where it exhibits some of the highest morbidity and mortality rates in the European Union. The Mediterranean diet has been suggested to reduce the incidence of CRC, but comprehensive evidence from diverse study designs is needed to substantiate this effect. A systematic literature search was conducted in PubMed, ClinicalTrials.gov, CENTRAL, and the Web of Science to identify randomized controlled trials and human clinical trials from 2008 to 2024 to identify relevant studies. Statistical analysis was performed using the https://metaanalysisonline.com web application using a random effects model to estimate the pooled hazard rates (HRs). Forest plots, funnel plots, and Z -score plots were utilized to visualize results. We identified 15 clinical trials and 9 case–control studies, encompassing a total of 2,217,404 subjects. The pooled analysis indicated that adherence to the Mediterranean diet significantly reduced the prevalence of CRC (HR = 0.84, 95% CI = 0.78–0.91, p  < 0.01). This protective effect was consistent across sexes, with HRs of 0.85 (95% CI = 0.75–0.97, p  = 0.01) for males and 0.88 (95% CI = 0.79–0.99, p  = 0.03) for females. Case–control studies specifically showed a substantial effect (HR = 0.51, 95% CI = 0.38–0.68, p  < 0.01). Notable heterogeneity was observed across studies, yet the a priori information size was substantially below the cumulative sample size, ensuring sufficient data for reliable conclusions. The findings from this meta-analysis reinforce the protective role of the Mediterranean diet against CRC. The results of this meta-analysis will inform dietary interventions designed to mitigate CRC risk, which are conducted within the framework of the Semmelweis Study, an ongoing comprehensive cohort study at Semmelweis University, designed to explore the multifaceted causes of unhealthy aging in Hungary. These interventions aim to explore the practical application of Mediterranean dietary patterns in reducing CRC incidence among the Hungarian population.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Witalisz-Siepracka, A.
AU  - Denk, C.-M.
AU  - Zdársky, B.
AU  - Hofmann, L.
AU  - Edtmayer, S.
AU  - Harm, T.
AU  - Weiss, S.
AU  - Heindl, K.
AU  - Hessenberger, M.
AU  - Summer, S.
AU  - Dutta, S.
AU  - Casanova, E.
AU  - Obermair, G.J.
AU  - Győrffy, Balázs
AU  - Putz, E.M.
AU  - Sill, H.
AU  - Stoiber, D.
TI  - STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance
JF  - FRONTIERS IN IMMUNOLOGY
J2  - FRONT IMMUNOL
VL  - 15
PY  - 2024
PG  - 15
SN  - 1664-3224
DO  - 10.3389/fimmu.2024.1374068
UR  - https://m2.mtmt.hu/api/publication/35151889
ID  - 35151889
N1  - Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, Krems, Austria            
            Division Physiology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, Krems, Austria            
            Department for Biomedical Research, University for Continuing Education Krems, Krems, Austria            
            Division of Oncology, Medical University of Graz, Graz, Austria            
            Institute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria            
            Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria            
            Department of Bioinformatics, Semmelweis University, Budapest, Hungary            
            Department of Biophysics, Medical School, University of Pecs, Pecs, Hungary            
            Cancer Biomarker Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary            
            St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria            
            Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria            
            Division of Hematology, Medical University of Graz, Graz, Austria            
            Export Date: 15 August 2024            
            Correspondence Address: Stoiber, D.; Division Pharmacology, Austria; email: dagmar.stoiber@kl.ac.at
LA  - English
DB  - MTMT
ER  -